Medtronic has announced a partnership with medical device company incubator The Foundry to invest in, and create, a company with the goal of developing an innovative transcatheter mitral repair technology (TMVr).
The partnership combines Medtronic’s knowledge in structural heart and intellectual property with The Foundry’s track record of innovation in the field of transcatheter mitral valve repair and replacement. The arrangement provides for structured investment tranches from both Medtronic and The Foundry and includes an exclusive right for Medtronic to acquire the resulting company, Half Moon Medical, contingent upon the achievement of certain technical and clinical milestones.
Half Moon recently received U.S. FDA approval of an early feasibility study in patients with severe, symptomatic mitral regurgitation and expects first implants in the coming weeks.
Nina Goodheart, president of the coronary & structural Heart division, said: “We have been encouraged by Half Moon’s development to date, leveraging Medtronic’s investment and intellectual property coupled with decades of mitral valve therapy experience at The Foundry through their development of repair and replacement technologies, including the Medtronic Intrepid valve. We believe this technology is promising and differentiated from other approaches to mitral valve repair.”
Half Moon Medical’s TMVr device restores function in a diseased mitral valve by filling the regurgitant orifice, creating a new coaptation surface for the native anterior leaflet. The device is fully repositionable and recoverable during deployment using a transfemoral delivery catheter, which assists physicians in navigating the vasculature and delivering the device to the diseased native mitral valve.
Hanson Gifford, president and CEO, The Foundry, said: “The result of testing more than 30 early concepts and design iterations, the Half Moon mitral repair device is a truly innovative solution that is designed to address multiple mitral regurgitation etiologies. Most importantly, similar to mitral valve replacement, this repair device has the potential to fully eliminate mitral regurgitation. It also maintains the physiologic function of the mitral valve and preserves options for re-intervention.”
The Half Moon device has the potential to complement Medtronic’s Intrepid Transcatheter Valve Replacement System, a mitral valve replacement device currently being studied in the APOLLO Pivotal Trial, a trial approved by the U.S. Food and Drug Administration (FDA) for Transcatheter Mitral Valve Replacement (TMVR).